← Back to all trials
Not Yet Recruiting
NCT05742061
Intra-articular Platelet Rich Plasma vs Corticosteroid in Treatment of Knee Osteoarthritis Patients
Conditions: Osteoarthritis Knee, Corticosteroid, Platelet Rich Plasma
Sex: All
Ages: 40 Years – 70 Years
Healthy volunteers: 1
Phase: EARLY_PHASE1
Enrollment: 100
Sponsor: Benha University
Summary
Knee osteoarthritis is the most common type of osteoarthritis in the lower extremity and constitutes 23% of all arthritis cases, about 13% of females and 10% of males aged above 60 years have symptomatic knee OA.
Intra-articular corticosteroids (IACs) are a frequently-used treatment regimen for pain relief from symptomatic knee OA as it inhibits inflammation and reduces prostaglandin synthesis.
Platelet-rich plasma (PRP) is an autologous blood product containing a high percentage of various growth factors (GFs), such as fibroblast growth factor, epidermal growth factor, vascular endothelial growth factor, transforming growth factor-β and platelet-derived growth factor.
The aim of this study is to compare effect of intra-articular injection of platelet rich plasma versus corticosteroid in treatment of primary knee osteoarthritis.
Eligibility Criteria
Inclusion Criteria:Patients 40-70 years of age suffering from knee OA with Kellgren Lawrence grade II or III on standing antero-posterior and lateral knee radiographs.Patients diagnosed according to ACR classification criteria.Exclusion Criteria:Systemic diseases as Patients having diabetes mellitus,Cardiovascular diseases or coagulopathies.Those receiving treatment with anticoagulant , anti_platelet medications or systemic corticosteroid 10 days before injection or recent use of NSAIDs.Pregnant and breast feeding females.Patients have hemoglobin values <10 g/dl or platelet values<150,000/ml.
Source: ClinicalTrials.gov (NCT05742061). StuddyBuddy aggregates publicly available trial information.